Neurodegenerative diseases are an increasingly important issue in our society. There are, however, still many obstacles on the way to finding methods for the cure. This table is intended to give an overview over neurodegenerative drugs that are currently in research and development, providing the reader with an idea about the complexity of drug
Glossary
No Development Reported: No evidence of continuing development has been reported for the past 18 months.
Discontinued: Confirmation from the company source that in-house development has been terminated.
Research Tool: Compounds that are not used as a drug, but are needed to investigate the function of a specific compound, which might result in a drug.
Discovery: Late research state, preparation for human testing: adaptation of research chemical synthesis (mg) to larger scale (kg), selection of salt form, selection of galenical form, design of clinical proof of concept studies, definition of endpoints, selection of biomarkers for clinical testing, additional safety testing, IND (investigational new drug) filing, clinical ethical review boards.
Phase 1: Clinical testing: tolerance in humans, repeated dosing, some escalation; proof of therapeutic concept or mechanism using scientific evaluation methods in a limited number of volunteers or patients.
Phase 2: Dose-finding studies, statistics, double blind studies.
Phase 3: Proof of efficacy, comparison to standard therapy, statistics, double blind studies with up to thousands of patients. Final phase of testing before registration and license to market.
